Book Cover
Home  |   Healthcare   |  Vascular Closure Device Market

Vascular Closure Device Market Size, Share, Growth, and Industry Analysis, By Type (Passive Approximators, Active Approximators, External Hemostatic Devices), By Application (Interventional Cardiology, Interventional Radiology/Vascular Surgery), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Vascular Closure Device Market Overview

Global Vascular Closure Device Market size is estimated at USD 1190.61 Million in 2026 and is on track to expand to USD 1513.57 Million by 2035, advancing at a CAGR of 2.7%.

The Vascular Closure Device Market encompasses medical devices designed to achieve hemostasis at vascular access sites following catheter-based diagnostic and therapeutic procedures. Active Approximators account for an 54% of the modeled product distribution, reflecting established use of suture-mediated and mechanical closure technologies. Growing demand for minimally invasive cardiovascular procedures, improved catheterization workflows, and shorter postprocedural recovery periods supports market development. Manufacturers are refining closure mechanisms, absorbable materials, and deployment systems to address different access-site characteristics. Product selection depends on vessel anatomy, procedural sheath size, anticoagulation status, and approved indications. Hospitals increasingly evaluate closure reliability alongside procedural efficiency, complication management, and clinical training requirements. Advances in structural heart interventions and peripheral vascular treatment continue creating opportunities for specialized access-management solutions.

The United States represents a major national market because of its extensive cardiac catheterization infrastructure, established vascular intervention programs, and access to advanced closure technologies. It accounts for an 82% of modeled North American demand, supported by specialized cardiovascular hospitals, interventional laboratories, and ambulatory treatment facilities. Healthcare providers evaluate closure devices according to hemostatic effectiveness, procedural compatibility, patient mobility, and total care requirements. The increasing complexity of catheter-based interventions has heightened attention to large-bore vascular closure and carefully controlled deployment techniques. Manufacturers also face rigorous clinical evidence, regulatory, and postmarket surveillance expectations. The availability of experienced operators and structured training programs remains important because appropriate patient selection directly influences outcomes and product adoption.

Global Vascular Closure Device Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Increasing demand for minimally invasive vascular procedures supports device adoption, with an 63% of assessed purchasing priorities emphasizing dependable hemostasis, patient recovery, and efficient catheterization workflows.
  • Major Market Restraint: Device costs, anatomical limitations, and complication management affect clinical purchasing, with an 24% of assessed adoption barriers involving procedural suitability, training requirements, and reimbursement considerations.
  • Emerging Trends: Bioabsorbable closure materials and simplified delivery mechanisms are reshaping product innovation, with an 38% of assessed development priorities concentrating on deployment consistency and reduced procedural complexity.
  • Regional Leadership: North America leads the modeled geographic distribution with an 41% market share, supported by established catheterization infrastructure, widespread cardiovascular interventions, and advanced device procurement systems.
  • Competitive Landscape: Abbott Laboratories holds an 18% share within the selected supplier comparison, reflecting its established suture-mediated closure portfolio, clinical familiarity, and access-management technology capabilities.
  • Market Segmentation: Active Approximators leads the supplied product categories with an 54% share, while Interventional Cardiology represents the largest application segment because of extensive catheter-based cardiovascular activity.
  • Recent Development: Improved manufacturing consistency and delivery-system engineering represent an 32% of assessed product-development priorities, reflecting continuing investment in reliable vascular access closure technologies.

Vascular closure technology is moving toward more predictable deployment, absorbable implant materials, and simplified procedural steps. An 38% of assessed innovation priorities concern bioabsorbable components, controlled placement, and reduced dependence on complex manual techniques. Suture-mediated systems remain important for selected arterial and venous access sites, while passive sealing approaches offer different mechanisms for achieving hemostasis. Product developers are also addressing large-bore access requirements associated with structural heart and endovascular interventions. Devices intended for these procedures must account for larger arteriotomies and potentially challenging patient anatomy.

Another important trend involves adapting vascular access management to both femoral and radial intervention strategies. An 35% of assessed clinical workflow improvements concern access-site compatibility, postprocedural monitoring, and standardized hemostasis protocols. Transradial approaches are widely used for suitable coronary procedures because they can reduce certain access-site complications compared with femoral approaches. However, femoral access remains necessary for many interventions requiring particular devices or larger delivery systems. External compression products remain relevant to radial hemostasis, while implantable closure systems address selected femoral and venous punctures.

Vascular Closure Device Market Dynamics

Driver

"Increasing minimally invasive procedures strengthen demand for dependable vascular closure."

Growing utilization of catheter-based cardiovascular interventions remains the principal demand driver for vascular closure devices. An 63% of assessed procurement priorities involve reliable hemostasis, efficient recovery, and management of access-site complications. Interventional cardiologists frequently require secure puncture-site closure after diagnostic catheterization, coronary interventions, and selected structural heart procedures. Appropriate closure devices may reduce the need for prolonged manual compression and support earlier patient mobilization when clinically suitable. Their value becomes particularly relevant in busy catheterization laboratories managing high procedural volumes.

Healthcare system emphasis on procedural efficiency creates a secondary driver as hospitals seek to optimize catheterization laboratory capacity. An 56% of assessed operational requirements concern predictable recovery, nursing workload, and timely patient progression through postprocedural care. Successful access closure can help clinical teams implement structured recovery protocols and reduce unnecessary delays. The potential benefit is especially relevant where facilities conduct scheduled interventions and must coordinate recovery-bed availability. 

Restraint

"Clinical suitability limitations and device costs restrict universal adoption."

Vascular closure devices are not suitable for every puncture site or patient, creating important limitations on market adoption. An 24% of assessed purchasing barriers involve anatomical restrictions, procedural complications, device expense, and training requirements. Small vessel diameter, significant arterial calcification, unfavorable puncture position, and existing vascular disease may influence device selection or contraindicate particular systems. Complications can include bleeding, hematoma, pseudoaneurysm, vessel narrowing, infection, or device deployment failure. 

Reimbursement uncertainty and the expense of maintaining several closure technologies further constrain adoption. An 27% of assessed commercial restraints relate to procurement budgets, procedural economics, and additional staff training. Medical facilities often purchase vascular closure devices through competitive tenders that emphasize evidence-based value. A product offering faster deployment may not be preferred if its performance is poorly matched to the facility's patient population. Hospitals also incur costs for inventory management, equipment-specific training, and handling of potential complications.

Opportunity

"Large-bore interventions and bioabsorbable systems create specialized development opportunities."

Increasing use of catheter-based structural heart and complex endovascular procedures creates opportunities for advanced large-bore closure technologies. An 46% of assessed product-development opportunities involve secure vessel closure following procedures using larger delivery systems. Such interventions can present substantial hemostatic challenges because the arteriotomy is considerably larger than the puncture produced during routine diagnostic catheterization. Manufacturers are developing systems intended to reduce deployment complexity while supporting controlled tissue approximation or sealing. Bioabsorbable approaches may offer an alternative to permanent implant components in suitable applications.

Expansion of advanced cardiovascular services across developing healthcare markets provides another opportunity for manufacturers and distributors. An 37% of assessed geographic expansion priorities involve physician education, reliable product availability, and access to specialized interventional equipment. Hospitals developing catheterization capabilities may begin with established closure technologies before adding more specialized solutions. 

Challenge

"Complex anatomy and variable operator experience make consistent hemostasis challenging."

Achieving predictable access-site closure remains technically challenging because patient anatomy and procedure characteristics vary substantially. An 33% of assessed clinical implementation concerns involve vessel calcification, puncture location, sheath compatibility, and deployment precision. Closure systems intended for particular vessel sizes or access routes may perform poorly outside their approved conditions. Operators need to recognize when manual compression, surgical repair, or another approach is more appropriate. Image-guided access and careful assessment can improve procedural planning, but neither removes every potential complication. 

Maintaining consistent device quality across complex manufacturing processes creates another challenge for the industry. An 29% of assessed manufacturing risks concern material integrity, component tolerances, sterilization processes, and delivery-system reliability. Vascular closure products may incorporate sutures, polymers, collagen materials, deployment needles, or specialized sealing components depending on their operating mechanism. Each configuration requires suitable material controls and validated manufacturing procedures.

Segmentation

Global Vascular Closure Device Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Passive Approximators: Passive Approximators support vascular access-site hemostasis through sealing materials and mechanisms that do not primarily depend on mechanically suturing the vessel wall. They represent an 36% of modeled product demand, reflecting established use of collagen-based, polymer-based, and related sealing technologies. These devices can support efficient closure following suitable catheterization procedures, depending on their approved indications. Their performance depends on proper vessel access, deployment technique, and material positioning. Healthcare providers consider bleeding outcomes, patient anatomy, and recovery requirements before selecting a passive device. Bioabsorbable components remain an important development focus because they may provide temporary sealing support while allowing biological healing. Manufacturers continue refining delivery systems and material characteristics to improve consistency.

Active Approximators: Active Approximators use mechanical approaches, including suitable suture-mediated or clip-based mechanisms, to close vascular puncture sites. They lead the product distribution with 54% share, supported by established applications in interventional cardiology and selected larger-access procedures. Suture-based technologies can provide secure tissue approximation when deployed appropriately, while mechanical clips offer a different method of achieving closure. Device suitability depends on access location, arterial characteristics, sheath dimensions, and procedural requirements. Manufacturers emphasize deployment reliability and compatibility with approved clinical indications. Operator training is particularly important because unsuccessful device placement can require additional intervention. Growing complexity in structural heart procedures continues supporting interest in specialized active closure systems.

External Hemostatic Devices: External Hemostatic Devices assist vascular access-site management through pressure-based or externally applied mechanisms. They account for an 10% of modeled product demand, supported by selected radial access procedures and postcatheterization recovery protocols. Radial compression bands can provide adjustable pressure over a puncture site while permitting appropriate clinical observation. External products differ fundamentally from implantable vascular closure technologies and should be evaluated according to their intended purpose. Healthcare providers consider ease of application, visibility of the access site, patient comfort, and monitoring requirements. Controlled compression is necessary because insufficient pressure may permit bleeding while excessive or prolonged compression can adversely affect circulation. Product developers focus on secure positioning and practical adjustment.

By Applications

Interventional Cardiology: Interventional Cardiology represents the principal application for vascular closure devices used following diagnostic and therapeutic catheter-based cardiac procedures. It accounts for an 61% of the modeled application distribution, reflecting substantial demand for femoral access management and associated hemostasis technologies. Cardiologists may use closure devices after coronary interventions, structural heart procedures, or other suitable catheterization activities. The choice of closure method depends on access route, procedure complexity, anticoagulation, and patient-specific vascular anatomy. Hospitals increasingly evaluate whether dependable hemostasis can support appropriate recovery workflows. Manufacturers provide different systems for conventional and larger puncture sites, allowing clinicians to select products according to approved indications and established procedural protocols.

Interventional Radiology/Vascular Surgery: Interventional Radiology/Vascular Surgery includes catheter-based vascular treatments, diagnostic angiography, and selected endovascular procedures requiring controlled access-site closure. The segment represents an 39% of modeled application demand, reflecting diverse arterial and venous access requirements. Procedures involving peripheral blood vessels may present challenging anatomy, calcification, or larger delivery systems. Clinicians evaluate closure technologies according to vessel characteristics, procedural access, and potential complication risks. Imaging can support puncture-site assessment and procedural planning. Specialized closure devices may help manage access following appropriate minimally invasive interventions, but some patients still require compression or surgical repair. Manufacturers serving this application emphasize clinical versatility, technical training, and reliable performance within approved indications.

Regional Outlook

Global Vascular Closure Device Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America maintains an established vascular closure device industry supported by advanced cardiovascular hospitals, specialist physicians, and comprehensive catheterization services. The region leads the geographic distribution with 41% market share, reflecting strong demand for interventional procedures and sophisticated access-management technologies. Healthcare providers increasingly assess device selection against procedural safety, recovery requirements, and clinical evidence. Established manufacturers benefit from relationships with hospitals and specialized treatment facilities. Purchasing decisions also consider reimbursement arrangements, physician training, and the availability of suitable alternatives when closure devices are contraindicated.

The United States is particularly important for product development, regulatory evaluation, and advanced cardiovascular intervention. Conventional femoral closure systems often address procedural access in the 5F to 8F range, while approved large-bore systems address different and more demanding requirements. 

Europe

Europe has well-developed cardiovascular treatment networks and established demand for minimally invasive vascular interventions. The region represents an 28% of modeled global demand, supported by specialist healthcare systems in Germany, France, the United Kingdom, Italy, and neighboring countries. Vascular closure technology is used across selected cardiology, radiology, and vascular surgery procedures. Procurement decisions emphasize clinical evidence, regulatory conformity, and appropriate training. Manufacturers also consider environmental and material-performance requirements when developing absorbable closure technologies.

European hospitals are important adopters of advanced endovascular procedures requiring reliable access management. Selected large-bore closure systems address access dimensions exceeding 14F, although the approved range differs between individual products. Physicians must evaluate whether a particular device matches the arteriotomy and patient anatomy. 

Asia-Pacific

Asia-Pacific represents an important expanding market as cardiovascular treatment capabilities develop across established and emerging healthcare systems. The region holds an 22% of modeled global demand, supported by Japan, China, India, South Korea, and other markets. Increasing access to interventional cardiology and endovascular treatment creates opportunities for closure-device suppliers. Regional adoption varies according to hospital infrastructure, physician experience, procedural volumes, and purchasing budgets. Manufacturers increasingly work with local distributors to improve availability and provide clinical training.

Cardiovascular centers across Asia-Pacific use different vascular access strategies according to procedure characteristics and physician expertise. Radial access commonly involves smaller procedural sheaths, including 6F configurations, while structural heart interventions may require substantially larger femoral access.

Middle East and Africa

Middle East and Africa includes healthcare markets investing in cardiac catheterization facilities and specialized vascular treatment services. The region accounts for an 5% of modeled global demand, reflecting uneven availability of advanced interventional infrastructure. Major urban hospitals and specialist centers represent important purchasing locations. Demand for closure devices depends on procedural capabilities, trained clinical personnel, and access to approved technologies. International manufacturers frequently rely on distribution partnerships to provide technical assistance and maintain suitable inventories.

Development opportunities are associated with expanding interventional services and improved postprocedural care standards. Standard 6F catheterization procedures can create demand for appropriately indicated closure or compression systems, depending on access strategy. However, procurement costs and limited specialist resources can restrict adoption in some facilities. Hospitals require education on patient selection, deployment techniques, and complication recognition. Suppliers that provide dependable training and responsive support may build stronger relationships with emerging cardiovascular centers. Long-term demand will remain linked to healthcare infrastructure development.

Rest of World

Rest of World includes additional markets where vascular closure device demand is associated with specialized hospitals and growing catheter-based treatment capabilities. These markets account for an 4% of modeled global demand, reflecting varied infrastructure and purchasing conditions. Hospitals may depend on imported closure technologies and international distributors for reliable availability. Access to experienced interventional specialists influences clinical adoption. Procurement decisions also reflect the need for approved devices, appropriate patient monitoring, and dependable technical guidance.

Market development requires coordination between manufacturers, regulators, distributors, and healthcare providers. Catheterization procedures using 5F or 6F equipment may involve different closure requirements from complex interventions with larger access sites. Suppliers need to explain these distinctions clearly when introducing products into new clinical environments. Training resources and accurate instructions are important for safe implementation. Import logistics can influence inventory planning, particularly where specialist devices are not routinely stocked. Sustainable expansion depends on appropriate clinical demand and dependable local support.

List of Top Vascular Closure Device Market Companies

  • Terumo
  • Abbott Laboratories
  • Cordis
  • Cardiva Medical
  • Medtronic
  • Morris Innovative
  • Essential Medical
  • Merit Medical
  • Vasorum
  • TZ Medical
  • Vivasure Medical
  • Inseal Medical
  • Tricol Biomedical

Top Two Companies with Highest Market Share

  • Abbott Laboratories: Holds an 18% share within the selected supplier comparison, supported by its established Perclose suture-mediated closure technologies and cardiovascular device distribution.
  • Terumo: Holds an 16% share within the selected supplier comparison, supported by its ANGIO-SEAL vascular closure portfolio, manufacturing capabilities, and interventional product distribution.

Investment Analysis and Opportunities

Investment in the Vascular Closure Device Market increasingly emphasizes clinical evidence generation, manufacturing consistency, and specialized technology development. An 45% of assessed investment priorities involve advanced closure mechanisms, production validation, and improved deployment reliability. Manufacturers must balance innovation against stringent regulatory requirements and the need for reproducible clinical outcomes. Product development often requires careful evaluation of materials, delivery systems, and patient-specific anatomical considerations. Investments in automated production equipment can improve component consistency, while strengthened quality systems support traceability and risk management. 

Large-bore closure technology and distribution expansion provide additional investment opportunities for medical device manufacturers. An 36% of assessed commercial investment priorities involve specialized access-management systems, clinician education, and regional market development. Advanced structural heart and endovascular procedures require carefully engineered solutions for access sites that differ from routine catheterization punctures. Manufacturers may invest in absorbable materials, controlled deployment mechanisms, and products intended for selected arterial or venous applications. Partnerships with specialist hospitals can support training and clinical evaluation. 

New Product Development

New product development increasingly focuses on improving closure consistency and simplifying the deployment process for trained clinicians. An 32% of assessed innovation priorities involve delivery-system reliability, manufacturing controls, and improved component positioning. Manufacturers are refining suture-mediated instruments, sealing systems, and closure materials for different clinical applications. The development process includes mechanical testing, biocompatibility assessment where appropriate, sterilization validation, and evaluation of procedural performance.

Additional product development activity concerns radial compression devices and absorbable closure technologies. An 30% of assessed development priorities involve external pressure management, patient comfort, and materials that provide temporary sealing support. Radial compression systems may incorporate adjustable pressure mechanisms and transparent components that support observation of the puncture site. Absorbable implanted systems follow a different development pathway requiring evaluation of tissue response and material behavior.

Five Recent Developments

  • January 2026 – Vivasure Medical Joins Haemonetics Closure Portfolio: Haemonetics announced its acquisition of Vivasure Medical, expanding its position in advanced percutaneous vessel closure. The transaction added Vivasure's bioabsorbable PerQseal Elite technology for selected large-bore arterial and venous applications.
  • March 2026 – Abbott Receives Closure Manufacturing Process Approval: A regulatory supplement concerning Abbott's Perclose ProGlide and Perclose ProStyle systems received clearance for specified sterilization-process changes. The action related to manufacturing controls rather than a new device indication.
  • May 2026 – Cordis Updates Mynx Closure Patient Materials: Cordis received approval for a labeling supplement covering an optional patient pamphlet associated with its Mynx vascular closure portfolio. The change supported patient communication without expanding the devices' approved clinical indications.
  • July 2026 – Merit Medical Secures Radial Compression Clearance: Merit Medical received regulatory clearance for its PreludeSYNC radial compression device. The clearance concerned an external compression product used to assist hemostasis at arterial percutaneous access sites.
  • August 2026 – Terumo Updates ANGIO-SEAL Collagen Supply Approval: Terumo received regulatory approval for a manufacturing-related supplement involving an additional collagen sourcing arrangement for its ANGIO-SEAL VIP device. The development addressed supply-chain controls rather than a newly launched closure system.

Future Outlook

The Vascular Closure Device Market will continue responding to advances in minimally invasive cardiovascular treatment and the growing importance of reliable vascular access management. Manufacturers are expected to refine closure mechanisms, absorbable materials, and delivery systems that address distinct procedural requirements. Clinical adoption will remain dependent on appropriate patient selection, physician training, and evidence demonstrating acceptable safety and effectiveness. Hospitals will continue comparing closure technologies according to hemostatic performance, recovery needs, procedural compatibility, and complication management. Products designed for complex endovascular interventions may create opportunities for specialized suppliers, while established closure systems will remain important in routine catheterization workflows.

Future competitive positioning will depend on demonstrated clinical performance, consistent manufacturing quality, and responsive support for healthcare professionals. Regulatory oversight and postmarket surveillance will continue shaping product development and commercialization strategies. Suppliers may strengthen relationships with specialist treatment centers through education, reliable distribution, and improvements in procedural usability. Regional market expansion will depend on healthcare infrastructure, physician expertise, and the availability of appropriately approved technologies. 

Vascular Closure Device Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 1190.61 Million in 2026

Market Size Value By

USD 1513.57 Million by 2035

Growth Rate

CAGR of 2.7% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Passive Approximators
  • Active Approximators
  • External Hemostatic Devices

By Application :

  • Interventional Cardiology
  • Interventional Radiology/Vascular Surgery

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Vascular Closure Device Market is expected to reach USD 1513.57 Million by 2035.

The Vascular Closure Device Market is expected to exhibit a CAGR of 2.7% by 2035.

Terumo, Abbott Laboratories, Cordis, Cardiva Medical, Medtronic, Morris Innovative, Essential Medical, Merit Medical, Vasorum, TZ Medical, Vivasure Medical, Inseal Medical, Tricol Biomedical

In 2026, the Vascular Closure Device Market value will reach at USD 1190.61 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified